TheresaLouiseWernerMD
Oncology • Salt Lake City, UTBreast Cancer, Cancer Genetics/Cancer Risk Assessment, Gynecologic Cancer, Hematologic Oncology
Associate Professor, Division of Oncology, Department of Medicine, University of Utah; Medical Director Clinical Trials Office at Huntsman Cancer Institute
Dr. Werner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2000 Circle of Hope Dr
Suite 2100
Salt Lake City, UT 84112Phone+1 801-585-0255Fax+1 801-585-0721- Is this information wrong?
Summary
- Dr. Theresa Werner is an oncologist in Salt Lake City, UT and is affiliated with University of Utah Health. She received her medical degree from Indiana University School of Medicine and has been in practice 17 years. She specializes in breast cancer, cancer genetics/cancer risk assessment, gynecologic cancer, and hematologic oncology and is experienced in hematologic oncology, breast cancer, and gynecologic oncology.
Education & Training
University of Utah HealthFellowship, Hematology and Medical Oncology, 2004 - 2007- University of Utah HealthResidency, Internal Medicine, 2000 - 2003
Indiana University School of MedicineClass of 2000
Certifications & Licensure
UT State Medical License 2001 - 2026
Clinical Trials
- Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
- Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
- Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. Start of enrollment: 2014 Jun 27
- Join now to see all
Publications & Presentations
PubMed
- Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors.Kang, Y., Ryu, M., Hong, Y., Choi, C., Kim, T., Ryoo, B., Kim, J., Kingsford, R., Park, C., Jang, S., McGinn, A., Sharma, S., Weis, J., Werner, T.> ;Cancer Research and Treatment. 2024 Jan 18
- Multi-Institutional Analysis of Cancer Patient Exposure, Perceptions, and Trust in Information Sources Regarding Complementary and Alternative Medicine.Ryan J Hutten, Christopher R Weil, Andy J King, Brandon Barney, Carma L Bylund, Angela Fagerlin, David K Gaffney, David Gill, Laura Scherer, Gita Suneja, Jonathan D Tw...> ;JCO Oncology Practice. 2023 Nov 1
- 1 citationsQuantifying the impact of the COVID-19 pandemic on cancer center clinical trial operations.Thomas J George, Tara L Lin, Tricia Adrales Bentz, Stefan Grant, Collette M Houston, Melissa A Nashawati, Bhanu Pappu, Helen Peck, Alex Zafirovski, Kimberly Kerstann, ...> ;JNCI Cancer Spectrum. 2023 Jul 3
- Join now to see all
Press Mentions
- Community DeathsMarch 16th, 2021
‘Beacon of Hope’: New Ovarian Cancer Drug Improves Survival Rates, Utah Doctors SayOctober 1st, 2019
Researchers Trace Timeline of Tumor Evolution in Metastatic Breast Cancer PatientsNovember 28th, 2017- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
University of Utah HealthSalt Lake City, Utah
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
